Stability of Botulinum Toxin in Clinical Use
The Food Research Institute currently produces all the Botulinum neurotoxin (Botox) used in the United States which is marketed as Oculinum (Allergan, Inc., Irvine, CA).1 Oculinum is packaged in freeze dried form in vials of 100 mouse units (MU) that require reconstitution with preservative free normal saline for clinical use. Although Ahe FDA recommends discarding toxin that is not used within 4 hours of reconstituting,2 there is little data describing Oculinum activity past this point.3 Information is also lacking regarding the effect of refreezing Botox that has been reconstituted for use at a later time.
KeywordsBotulinum Toxin Freezer Storage Cervical Dystonia Botulinum Neurotoxin Clostridium Botulinum
Unable to display preview. Download preview PDF.
- 2.Oculinum (Botulinum Toxin Type A) package insert, Irvine, CA: Allergan; Inc., (December, 1989 ).Google Scholar
- 3.A.B. Scott, Botulinum toxin injection of eye muscles to correct strabismus, Trans Am Ophthalmol Soc. 129: 735–751 (1981).Google Scholar
- 4.NIH Consensus Development Conference on Clinical Use of Botulinum Toxin. National Institute of Health, Bethesda Maryland (November 12–14, 1990 ).Google Scholar
- 5.H.T. Hoffman, and M.G. Gartlan, Stability of botulinum toxin in clinical use, Presentation at “Botulinum Tetanus Neurotoxins; Neurotransmission and Biomedical Aspects” International Conference. Madison, Wisconsin. (May 12, 1992 ).Google Scholar
- 6.M.G. Gartlan and H.T. Hoffman, Botulinum neurotoxin A: degradation in potency with storage, Submitted to Otolaryngol Head Neck Surg. (June, 1992 ).Google Scholar
- 7.C.L. Ludlow, Personal Communication. (May 12, 1992 ).Google Scholar
- 8.EJ. Schantz and D.A. Kautter, Standardized assay for clostridium botulinum toxins,JAssoc Off Anal Chem. 61: 1, (1978).Google Scholar
- 9.G.K. McCvoy and K. Litrak, eds, American hospital formulary service drug information. Bethesda MD: American Society of Hospital Pharmacists, Inc., 1951–2 (1991).Google Scholar